Press Releases

Date Title View
Toggle SummaryMarch 15, 2021 Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample
Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021 GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample GenMark’s ePlex platform delivers rapid and actionable
View HTML
Toggle SummaryFebruary 25, 2021 GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results
CARLSBAD, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020 .
View HTML
Toggle SummaryFebruary 22, 2021 GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico Analysis
CARLSBAD, Calif. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 ( RP2 ) is predicted to detect known SARS-CoV-2 variants
View HTML
Toggle SummaryFebruary 16, 2021 GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference
CARLSBAD, Calif. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41 st Annual
View HTML
Toggle SummaryFebruary 16, 2021 Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels
Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients CARLSBAD, Calif. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular
View HTML
Toggle SummaryFebruary 11, 2021 GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
CARLSBAD, Calif. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's
View HTML
Toggle SummaryJanuary 11, 2021 GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020
CARLSBAD, Calif. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020 .
View HTML
Toggle SummaryDecember 28, 2020 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , Dec. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.
View HTML
Toggle SummaryNovember 5, 2020 GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum
CARLSBAD, Calif. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual
View HTML
Toggle SummaryOctober 28, 2020 GenMark Diagnostics Reports Third Quarter 2020 Results
CARLSBAD, Calif. , Oct. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended September 30, 2020 .
View HTML